Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or ...
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741 MSI assay or ...
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in ...
A retrospective study found that patients with mismatch repair (MMR)-deficient advanced or recurrent endometrial cancer had numerically longer overall survival (OS) than those with MMR-proficient ...
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104 No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2006 ASCO ...
Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant ...
CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing ...
A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results